Pro Medicus Limited (OTCMKTS:PMCUF – Get Free Report) shares were up 3.3% during trading on Friday . The stock traded as high as $92.95 and last traded at $87.85. Approximately 251 shares changed hands during trading, a decline of 67% from the average daily volume of 771 shares. The stock had previously closed at $85.01.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group set a $155.00 price target on Pro Medicus and gave the company a “buy” rating in a research note on Thursday, February 12th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Pro Medicus currently has a consensus rating of “Buy” and an average price target of $155.00.
View Our Latest Research Report on Pro Medicus
Pro Medicus Stock Up 3.3%
Pro Medicus Company Profile
Pro Medicus Limited is an Australia‐based healthcare technology company specializing in advanced medical imaging IT solutions. Its core offerings include radiology information systems (RIS), picture archiving and communication systems (PACS), and enterprise imaging platforms designed to streamline diagnostic workflows and enhance image management for healthcare providers.
The company’s flagship product suite, Visage 7, delivers high-performance visualization and reporting capabilities, enabling radiologists to access and manipulate large datasets with minimal latency.
Featured Stories
- Five stocks we like better than Pro Medicus
- From Quiet Compounder to 2026 Breakout? BSEM
- Unlocked: Elon Musk’s Next Big IPO
- What a Former CIA Agent Knows About the Coming Collapse
- Gilder: Don’t Buy AI Stocks, Do This Instead
- America’s 1776 happening again
Receive News & Ratings for Pro Medicus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro Medicus and related companies with MarketBeat.com's FREE daily email newsletter.
